A Phase 1/2 Study of Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Talimogene laherparepvec (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 24 Mar 2017 Status changed from not yet recruiting to recruiting.
- 25 Jan 2017 Planned initiation date changed from 1 Feb 2017 to 30 Apr 2017.
- 16 Nov 2016 Planned initiation date changed from 1 Nov 2016 to 1 Feb 2017.